Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. (Q45918155)
Jump to navigation
Jump to search
scientific article published on 28 July 2009
Language | Label | Description | Also known as |
---|---|---|---|
English | Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. |
scientific article published on 28 July 2009 |
Statements
1 reference
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. (English)
1 reference
1 reference
Lindsay A Brown
1 reference
Karynn Johnson
1 reference
Samuel Leung
1 reference
Tarek A Bismar
1 reference
Javier BenÃtez
1 reference
David G Huntsman
1 reference
28 July 2009
1 reference
121
1 reference
2
1 reference
347-354
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference